NCT04745910 2025-12-18
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
Clinical Trials
11 trialsNCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT04214093 2023-08-02
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
AstraZeneca
Phase 1 Terminated
NCT01200485 2020-01-31
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00445341 2018-01-30
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01724528 2014-11-03
FLORENCE
Menarini Group
Phase 3 Completed
NCT00628628 2013-08-01
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00360438 2012-08-01
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00230178 2010-01-12
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Sanofi
Phase 3 Completed
NCT00230217 2009-03-30
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Sanofi
Phase 4 Completed
NCT00651911 2008-04-03
Fasturtec TLS Treatment / Prophylysis
Sanofi
Phase 4 Completed